Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Int J Rheum Dis. 2019 Nov 27;23(3):294–301. doi: 10.1111/1756-185X.13756

Table 1.

Demographic and clinical characteristics of participants (n=177)a

Variable Mean ± SD
Age, yrs. 52.0 ± 12.2
Sex, n(%)
  Female 165(93.2)
Race, n(%)
  White 104(58.8)
  Other 73(41.2)
Level of Education, n (%)
  Less than College Degree 110 (62.2)
  College Degree or Higher 67 (37.8)
Body Mass Index, kg/m2 30.1 ± 6.7
Duration of disease, yrs. 13.1 ± 10.1
Pittsburgh Sleep Quality Index (Range: 0-21)* 11.7 ± 4.0
Five Facet Mindfulness Questionnaire
  Total (Range: 39-195) 131.3 ± 20.7
  Observing (Range: 8-40) 29.5 ± 5.7
  Describing (Range: 8-40) 27.8 ± 6.2
  Acting with Awareness (Range: 8-40) 24.9 ± 6.8
  Non-Judging (Range: 8-40) 27.4 ± 7.5
  Non-Reacting (Range: 7-35) 21.7 ± 4.9
PROMIS Pain Interference (Range: 41-78.3)* 65.2 ± 5.9
PROMIS Sleep Disturbance (Range 28.9-76.5)* 59.9 ± 7.8
Symptom Severity (Range: 0-12)* 8.7 ± 2.0
HADS-Depression (Range: 0-21)* 7.6 ± 4.1
HADS-Anxiety (Range: 0-21)* 8.9 ± 4.1
Revised Fibromyalgia Impact Questionnaire (Range: 0-100)* 57.0 ± 19.4
a

Values reported as mean ± SD unless otherwise noted

*

Indicates tests with higher scores indicating worse outcomes; better outcomes unmarked.

PROMIS Pain Interference and PROMIS Pain Interference reported in t-scores

PROMIS = Patient-Reported Outcomes Measurement Information System; HADS = Hospital Anxiety and Depression Scale